ERBB2 and cardiomyopathy: Two patients were HER2+, but one has been already treated with trastuzumab, developing a cardiac heart failure which precluded any other therapy with anti-HER2 agents; the second could not receive any anti-HER2 treatment due to the presence of severe cardiomyopathy.